You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Investigational Drug Information for BMS-986278


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for BMS-986278?

BMS-986278 is an investigational drug.

There have been 12 clinical trials for BMS-986278. The most recent clinical trial was a Phase 1 trial, which was initiated on September 14th 2023.

The most common disease conditions in clinical trials are Pulmonary Fibrosis, Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for BMS-986278
TitleSponsorPhase
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisBristol-Myers SquibbPhase 3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisBristol-Myers SquibbPhase 3
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female ParticipantsBristol-Myers SquibbPhase 1

See all BMS-986278 clinical trials

Clinical Trial Summary for BMS-986278

Top disease conditions for BMS-986278
Top clinical trial sponsors for BMS-986278

See all BMS-986278 clinical trials

US Patents for BMS-986278

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BMS-986278 ⤷  Subscribe Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists Bristol-Myers Squibb Company (Princeton, NJ) Syngene International Limited (Bangalore, Karnataka, IN) ⤷  Subscribe
BMS-986278 ⤷  Subscribe Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists Bristol-Myers Squibb Company (Princeton, NJ) ⤷  Subscribe
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BMS-986278

Drugname Country Document Number Estimated Expiration Related US Patent
BMS-986278 Argentina AR108838 2036-06-21 ⤷  Subscribe
BMS-986278 Australia AU2017281439 2036-06-21 ⤷  Subscribe
BMS-986278 Australia AU2021209334 2036-06-21 ⤷  Subscribe
BMS-986278 Brazil BR112018076558 2036-06-21 ⤷  Subscribe
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.